apollo

Select Address

Search Medicines
  • Login
  1. Home
  2. Kyprolis 60 mg Injection

  3. Kyprolis 60 mg Injection Substitute

Kyprolis 60 mg Injection Substitute

Substitutes safety advice
call Doctor

Verified Ingredients and Effects

Composition:

CARFILZOMIB-60MG

Uses:

Kyprolis 60 mg Injection is used in the treatment of Multiple Myeloma. The detailed uses of Kyprolis 60 mg Injection are as follows:<br/>• Relapsed or refractory multiple myeloma: Kyprolis 60 mg Injection is used for the treatment of multiple myeloma in adult patients whose cancer has relapsed or is refractory to one or more lines of therapy. It is specifically indicated when the disease becomes resistant to previous treatments, helping to slow disease progression and extend survival. By targeting cancer cells that have adapted to earlier therapies, Kyprolis 60 mg Injection provides a critical second-line or later treatment option.<br/>• Combination therapy support: Kyprolis 60 mg Injection is used in combination with other agents such as dexamethasone or lenalidomide to enhance overall treatment efficacy in patients with relapsed or refractory multiple myeloma. These combinations have shown improved response rates and longer progression-free survival compared to monotherapy. The synergy between Kyprolis 60 mg Injection and these medications helps increase cancer cell death while maintaining manageable toxicity profiles.<br/>• Proteasome inhibition in cancer therapy: Kyprolis 60 mg Injection is used as a selective proteasome inhibitor that blocks the activity of proteasomes, which are cellular structures responsible for breaking down unneeded or damaged proteins. In cancer cells, this inhibition disrupts protein homeostasis and causes toxic proteins to accumulate, leading to cellular stress and programmed cell death (apoptosis). By targeting the increased protein turnover demands of myeloma cells, Kyprolis 60 mg Injection effectively eliminates cancer cells while leaving most normal cells relatively unaffected.<br/>

Medicinal Benefits:

Carfilzomib, a proteasome inhibitor, is present in Kyprolis 60 mg Injection. It suppresses proteasomes, preventing protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.

FAQs

Kyprolis 60 mg Injection is used to treat Multiple Myeloma.

Kyprolis 60 mg Injection contains Carfilzomib, which inhibits proteasomes and thereby prevents protein breakdown in MM (multiple myeloma) cells. When the proteasome action within the MM cell is disturbed, a protein accumulation occurs, destroying the cancerous cells.

No, it is unsafe to father a child while taking Kyprolis 60 mg Injection. It is recommended for sexually active men to use condoms while on treatment and for at least several months after their last dose of Kyprolis 60 mg Injection.

Based on the medical condition, Kyprolis 60 mg Injection may be given alone or together with other medicines used to treat multiple myeloma.

Tell your healthcare professional immediately if you get any signs of an infusion-related reaction during or after the infusion. Your doctor may give other medicines, or the infusion may need to be slowed down or stopped.

Kyprolis 60 mg Injection can cause a significant decrease in the number of blood cells and platelets. Your doctor may suggest laboratory tests before and during the treatment. Tell your healthcare provider if you develop a fever or have signs of bruising or bleeding.

Kyprolis 60 mg Injection treats multiple myeloma that has returned or no longer responds to treatment. It's often used with other medications. If you have questions or concerns, talk to your doctor. They will help you understand if Kyprolis 60 mg Injection is right for you.

Kyprolis 60 mg Injection is to be administered by intravenous infusion in a hospital setting under the supervision of a physician qualified to administer cancer chemotherapeutic agents.

Kyprolis 60 mg Injection is given on two consecutive days each week for three weeks followed by a 12-day rest period or it may be given once a week for 3 weeks followed by a 13-day rest period. However, the pattern and duration of treatment may vary. Please consult the doctor if you have any concerns.

You may experience nausea and extreme tiredness from Kyprolis 60 mg Injection. To cope with nausea, try eating small meals, avoiding strong smells, and staying hydrated. For tiredness, prioritize rest, break tasks into smaller chunks, and take regular breaks. Practice relaxation techniques like deep breathing, meditation, or yoga, and stay hydrated and energized with nutritious food. However, if these are bothering you consult your doctor immediately.

Kyprolis 60 mg Injection can lower your blood cell and platelet counts, increasing the risk of infections, anemia, and bleeding. To keep an eye on this, your doctor will likely order regular blood tests before and during treatment. Consult your doctor if you suspect any symptoms of low immunity like delayed healing or frequent infections.

If you experience any of the following, seek a doctor's advice right away: fever, infection signs, unusual bleeding, shortness of breath, chest pain, severe nausea, weakness, confusion, or severe headache. Also, consult your doctor if you have concerns or questions about your treatment, notice any health changes or side effects, miss a dose, or need to change your treatment schedule.

Kyprolis 60 mg Injection should not be taken during pregnancy as it might cause fetal harm. Inform your doctor immediately if you are pregnant or think you may be pregnant while on therapy.

Do not breastfeed while you are receiving Kyprolis 60 mg Injection and for two weeks after your final dose as it may pass into the breastmilk. Consult your doctor if you have any concerns regarding it.